Alpha radiation therapy
Oncoinvent’s technology delivers alpha radiation directly to cancer cells to cause DNA damage.
oncoinvent.comCrawled Nov 11, 2026
Oncoinvent’s technology delivers alpha radiation directly to cancer cells to cause DNA damage.
Oncoinvent develops cancer therapeutics, including Radspherin, which is in clinical trials for peritoneal metastasis.
Oncoinvent’s pipeline includes radiopharmaceuticals using alpha-emitting radionuclides for solid cancers, with Radspherin in clinical development.
Radspherin is an alpha radiation therapy candidate using radium-224-loaded microparticles for localized cancer treatment.
Oncoinvent CEO Jan A. Alfheim speaks with Radforsk’s Jónas Einarsson and Elisabeth Kirkeng Andersen
Publications ALL20232022202120202019201820172016 Radiation safety considerations for the use of radium-224- calciumcarbonate-microparticles in patients with peritoneal metastasis. Grønningsæter, Blakkisrud, Selboe, Revheim, Bruland, Bønsdorff, Larsen, Caroline First experience with 224Radium-labeled microparticles (Radspherin) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study). S. Larsen , W. Graf, A. Mariathasan, O. Sørensen, M. Spasojevic, M. Goscinski, S. Selboe
Oncoinvent will present at the International Cancer Cluster Showcase at the BIO International Convention in Philadelphia.
News News and events Events Subscribe to news
The page lists news items about Oncoinvent’s funding, manufacturing authorization, distribution agreement, leadership appointments, and conference presentations.
this is the blueprint-page for the the news coming from CisionPointtitle: ##title##description: ##description##date: ##date##
Oncoinvent offers opportunities to join its radiopharma biotech team developing cancer therapies.
Oncoinvent is recruiting a process development technologist for its Oslo production department.
Oncoinvent seeks a quality control scientist for a temporary position at its Oslo manufacturing facility.
Oncoinvent is hiring a senior process development scientist for its Oslo-based production team.
Oncoinvent is hiring a senior production technician for its Oslo facility to contribute to pharmaceutical development.
The board of directors includes Gillies O’Bryan-Tear, Ingrid Teigland Akay, Kari Grønås, Hilde Steineger, Orlando Oliveira, Johan Häggblad, and Anne Cecile Alvik.
The executive team comprises Øystein Soug, Ramzi Amri, Zuzana Jiráková Trnková, Gro Hjellum, Kristine Lofthus, Sara Westrøm, and Anne-Kirsti Aksnes.
Scientific Advisory Board Roy Hartvig Larsen, PHD Chairman Read more + Øyvind Bruland, Prof. emerit. MD, PhD Board member Read more + About Management
Oncoinvent ASA is a Norwegian clinical-stage biotech company focused on alpha therapy for cancer treatment.
Oncoinvent’s contact details are located at Gullhaugveien 70 in Oslo, Norway.
IR Contact Ramzi Amri Chief Financial Officer amri@oncoinvent.com+47 22 18 33 05 IR contact: IR@oncoinvent.com Reports and presentations The Share General meetings
Oncoinvent ASA hosts a live webcast to share its third-quarter company update. The biotech firm specializes in developing a receptor-independent alpha radiopharmaceutical designed to target and eliminate residual cancer cells in the abdominal cavity post-surgery using a single, precise dose.
Oncoinvent ASA appoints Dr Zuzana Jiráková Trnková as Chief Medical Officer to oversee Phase 3 preparations for **Radspherin®**, its receptor-independent alpha-emitting therapy targeting residual cancer cells in the abdominal cavity. The treatment aims to deliver a single, targeted dose post-surgery. Dr Jiráková Trnková, an MD and PhD, replaces Kari Myren, who is departing for external opportunities. The company specializes in clinical-stage radiopharmaceuticals.
Oncoinvent ASA cancels its planned subsequent repair offering. The company restricts distribution of this announcement to jurisdictions where publication would be lawful. No details on financial impact or reasons for cancellation are provided.
Oncoinvent ASA completes a private placement of **1.53 million new shares** in two tranches (990,689 and 540,311 shares) alongside a **119,000-share retail offering** via Nordnet. The shares are now fully registered as part of the company’s updated share capital. The funding follows a stock exchange announcement detailing the allocation process.
Oncoinvent ASA raises capital through a successful private placement and retail offering. The company expands its funding base while adhering to restricted distribution rules in multiple jurisdictions. No further details on funding amounts or investor participation are disclosed.
Oncoinvent completes half of its Phase 2 trial patient recruitment for Radspherin®, a single-dose alpha-emitting therapy targeting peritoneal metastases from ovarian cancer. The study evaluates the treatment’s ability to eliminate cancer cells in the abdominal cavity post-surgery. Radspherin® operates independently of cancer cell receptors, aiming for targeted eradication with minimal systemic exposure.
Oncoinvent ASA announces the final results of its rights issue. The company completes the capital-raising process under regulatory restrictions excluding certain jurisdictions. Key details include adherence to distribution laws and applicable restrictions.
Oncoinvent ASA and BerGenBio ASA finalize their merger, with Oncoinvent dissolving and the combined entity adopting the name **Oncoinvent ASA**. The merger issues **117.55 million new shares** to former Oncoinvent shareholders, increasing the company’s total share capital to **NOK 156.64 million** across all shares.